<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817789</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/24</org_study_id>
    <nct_id>NCT02817789</nct_id>
  </id_info>
  <brief_title>Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)</brief_title>
  <acronym>TICTAVI</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic
      stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure
      and during few weeks after implantation in the aim to minimize cerebral embolization. But for
      now, the best antiplatelet regimen has to be determined. In this context, investigators want
      to evaluate the safety of use of ticagrelor alone versus standardized therapy which involves
      lysine acetylsalicylate and clopidogrel. In this study, we will randomly compare 154 patients
      in each group in terms of early safety (30 days) after the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In spite of the use of the combination of lysine acetylsalicylate and clopidogrel during and
      after the procedure of TAVI, rates of stroke remains high, between 4 and 10% regarding the
      studies and registries. None of the therapeutics have regulatory authorisation for this
      indication. On the other hand, the rates of bleeding events are also high in this old and
      frail population. That is why, considering its pharmacological specificity, investigators
      hypothesize that ticagrelor, used alone, could be non-inferior on safety criteria than the
      combination of lysine acetylsalicylate and clopidogrel. Our study want to evaluate the safety
      profile of Ticagrelor alone (180 mg loading dose before intervention and 90 mg twice daily
      during 30 days after the procedure) compared to the standardized treatment combining lysine
      acetylsalicylate (75 mg before and 75 mg daily after the procedure) and clopidogrel (300mg
      loading dose before and 75 mg daily after the procedure). Patients will be followed during
      one month. Then they will be all placed under the usual antiplatelet treatment (clopidogrel
      and lysine acetylsalicylate for two additional months and then lysine acetylsalicylate alone
      lifelong).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient presenting at least one event of the Valve Academic Research Consortium-2 (VARC2) composite endpoint</measure>
    <time_frame>Day 30</time_frame>
    <description>VARC2 composite endpoint :
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening or disabling bleeding
Acute kidney injury - Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patient died</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patient presenting stroke or Transient Ischemic Attack (TIA)</measure>
    <time_frame>Day 30</time_frame>
    <description>Diagnostic criteria: Acute episode of a focal or global neurological deficit with at least one of the following: change in the level of consciousness, hemiplegia, hemiparesis, numbness, or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke Stroke: duration of a focal or global neurological deficit &gt;24 h; OR &lt;24 h if available neuroimaging documents a new haemorrhage or infarct; OR the neurological deficit results in death TIA: duration of a focal or global neurological deficit &lt;24 h, any variable neuroimaging does not demonstrate a new hemorrhage or infarct</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patient presenting life-threatening bleeding</measure>
    <time_frame>Day 30</time_frame>
    <description>Life-threatening bleeding:
Fatal bleeding OR Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome OR Bleeding causing hypovolaemic shock or severe hypotension requiring vasopressors or surgery OR Overt source of bleeding with drop in haemoglobin &gt;5 g/dL or whole blood or packed red blood cells (RBCs) transfusion &gt;4 units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients presenting post-TAVI acute kidney failure stage 2 or 3 as assessed by VARC2</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients presenting angiographic or echographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the valve prosthesis itself, the native leaflets, calcifications, or dissection</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients presenting major vascular complications</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients requiring a new procedure like Balloon Aortic valvuloplasty (BAV), new procedure of TAVI or Surgical aortic valve replacement (SAVR)</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients presenting at least one conduction disturbance or arrhythmias</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients presenting at least one other TAVI related complication</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients presenting at least one bleeding event (life-threatening, major or minor)</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with good biological efficiency of the antiplatelet therapy assessed by VerifyNow (VN)</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with new cerebral event assessed by brain Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of high-intensity transient signals (HITS) assessed by transcranial Doppler</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the score of Mini Mental State Examination (MMSE)</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the Dubois's 5 words test</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the Geriatric Depression Scale (GDS)</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the basic Activities of Daily Living (ADL) questionnaire</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the Instrumental Activities of Daily Life (IADL) questionnaire</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status by the Short Form Health Survey (SF-12) questionnaire</measure>
    <time_frame>At baseline and day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>154 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>154 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor alone</intervention_name>
    <description>180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure</description>
    <arm_group_label>Ticagrelor group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination lysine acetylsalicylate - clopidogrel</intervention_name>
    <description>75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure</description>
    <arm_group_label>Standard group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female or male aged &gt; 18 years

          -  Patient eligible for TAVI as recommended by French health care system authority (HAS)

        Exclusion Criteria:

          -  Allergy, hypersensitivity, or contraindication to lysine acetylsalicylate,
             clopidogrel, ticagrelor, any anticoagulation or magnetic resonance imaging (MRI) or
             CT-scanner contrast agents

          -  Use of Cytochrome P3a (CYP3a) inhibitor

          -  Need for chronic anticoagulation

          -  Previous percutaneous coronary intervention or acute coronary syndrome requiring dual
             antiplatelet therapy

          -  Previous cardiac surgery for valve replacement

          -  Prior stroke, transient ischemic attack (TIA) or known carotid stenosis &gt; 70%

          -  Active pathological bleeding or gastric ulcer &lt; 3month

          -  Known thrombocytopenia, anemia or any coagulopathy

          -  Severe kidney or hepatic impairment

          -  Hemodynamic instability

          -  Refusal of Transfusion

          -  Significant mental impairment

          -  Inability to give informed consent or comply with study related procedures or high
             likelihood of being unavailable for follow-up

          -  Pregnant or breastfeeding women

          -  Women of childbearing potential without effective contraception (oestroprogestative,
             intrauterine devices)

          -  Participant in another investigational drug or device study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel LEROUX, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lionel LEROUX, Dr</last_name>
    <email>lionel.leroux@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile JORE</last_name>
    <email>cecile.jore@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric VANBELLE, Pr</last_name>
      <email>eric.vanbelle2@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bérénice MARCHANT</last_name>
      <email>berenice.marchant@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric VANBELLE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas CUISSET, Pr</last_name>
      <email>thomas.cuisset@.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas CUISSET, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume CAYLA, Pr</last_name>
      <email>cayla.guillaume@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chrystel LEPERCHOIS-JACQUEY</last_name>
      <email>leperchois.jacquey@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guillaume CAYLA, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe COLLET, Pr</last_name>
      <email>jean-philippe.collet@psl.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin BERTIN</last_name>
      <email>benjamin.bertin-ext@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Philippe COLLET, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel LEROUX, Dr</last_name>
      <email>lionel.leroux@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile JORE</last_name>
      <email>cecile.jore@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Lionel LEROUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina DIJOS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane LAFITTE, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric CASASSUS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin SEGUY, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PELTAN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Antiplatelet agent</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Cerebrovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Acetylsalicylic acid lysinate</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

